Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Keytruda Survival Benefits Similar to Chemo for Relapsed Mesothelioma, Phase 3 Trial Finds

November 6, 2019 By Law Offices of Thomas J. Lamb, P.A.

Treatment with the immunotherapy Keytruda (pembrolizumab) appears to be as effective as conventional chemotherapy for treating malignant pleural mesothelioma patients who relapse after one course of platinum-based chemotherapy, data from a Phase 3 trial show.

Although more of these advanced cancer patients responded to Keytruda than to chemotherapy, notable differences in survival were not seen. More study is needed to determine cancer patients most likely to benefit from immunotherapies, its researchers said.

These findings were in the poster, “A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial,” presented at the recent European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona.

Keytruda is an immune checkpoint inhibitor (developed by Merck; known as MSD outside the U.S. and Canada) that has been approved by the U.S. Food and Drug Administration and by the European Medicines Agency (EMA) to treat several types of cancer.

It is a monoclonal antibody that targets and blocks the activity of the PD-1 receptor (a protein found on the surface of immune cells), which cancer cells use to avoid being targeted and killed by immune cells.

PROMISE-meso (NCT02991482) is a Phase 3 trial comparing the efficacy of Keytruda to standard chemotherapy in people with advanced malignant pleural mesothelioma — a lethal form of cancer in the pleura, the protective lining around the lungs — who failed to respond to a previous course of platinum-based chemotherapy.

[Article continues at original source]

 Asbestos & Mesothelioma Information

  Asbestos-Mesothelioma Case Evaluation
Free.  Confidential.  No Obligation.

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.